Shares of biotechnology company Hillstream BioPharma (NASDAQ:HILS) are soaring in the pre-market session today on promising initial data from HSB-1216 for the treatment of non-small cell lung cancer (NSCLC).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The study, evaluating the combination of HSB-1216 and pembrolizumab, demonstrated a significantly greater tumor inhibition of calu-1 cells when grown with human PBMCs.
The results gain even more significance considering NSCLC makes up for 80% to 85% of all cancer-associated cases worldwide.
Shares of the company are up nearly 90% today. This is on top of the 205% gains the stock has posted over the past month alone!
Read full Disclosure